AC
PTCT icon

Armistice Capital’s PTC Therapeutics PTCT Stock Holding History

Armistice Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$141M Sell
2,074,449
-727,420
-26% -$51.5M 2.51% 4
2025
Q4 		$213M Sell
2,801,869
-475,403
-15% -$34.5M 2.53% 3
2025
Q3 		$201M Sell
3,277,272
-1,458,192
-31% -$76M 2.98% 3
2025
Q2 		$231M Sell
4,735,464
-699,379
-13% -$33.2M 3.99% 3
2025
Q1 		$277M Sell
5,434,843
-943,157
-15% -$47.1M 4.15% 3
2024
Q4 		$288M Sell
6,378,000
-856,898
-12% -$36.7M 3.93% 3
2024
Q3 		$268M Buy
7,234,898
+272,671
+4% +$9.13M 4.29% 3
2024
Q2 		$213M Buy
6,962,227
+198,227
+3% +$6.42M 2.68% 3
2024
Q1 		$197M Sell
6,764,000
-100,000
-1% -$2.8M 2.61% 3
2023
Q4 		$189M Buy
6,864,000
+714,000
+12% +$16.3M 2.58% 3
2023
Q3 		$138M Buy
6,150,000
+2,914,000
+90% +$108M 2.11% 4
2023
Q2 		$132M Buy
3,236,000
+312,000
+11% +$15.3M 1.9% 6
2023
Q1 		$142M Sell
2,924,000
-472,000
-14% -$21.6M 2.04% 6
2022
Q4 		$130M Buy
3,396,000
+496,000
+17% +$20.6M 2.26% 6
2022
Q3 		$146M Sell
2,900,000
-396,000
-12% -$19.4M 2.53% 5
2022
Q2 		$132K Buy
3,296,000
+260,000
+9% +$9.12M 2.3% 6
2022
Q1 		$113M Buy
3,036,000
+2,118,893
+231% +$81.6M 2.19% 6
2021
Q4 		$36.5M Sell
917,107
-1,678,893
-65% -$64.3M 0.6% 41
2021
Q3 		$96.6M Buy
2,596,000
+504,000
+24% +$20.7M 1.64% 12
2021
Q2 		$88.4M Buy
2,092,000
+696,000
+50% +$29.8M 1.58% 10
2021
Q1 		$66.1M Buy
1,396,000
+680,000
+95% +$40.4M 1.52% 15
2020
Q4 		$43.7M Sell
716,000
-8,000
-1% -$472K 1.49% 17
2020
Q3 		$33.8M Buy
724,000
+224,000
+45% +$11M 1.23% 26
2020
Q2 		$25.4M Sell
500,000
-100,000
-17% -$4.91M 1.11% 38
2020
Q1 		$26.8M Sell
600,000
-158,000
-21% -$7.96M 1.66% 20
2019
Q4 		$36.4M Buy
758,000
+622,000
+457% +$26.4M 2.1% 10
2019
Q3 		$4.6M Buy
+136,000
New +$5.92M 0.3% 55
2019
Q2 		– Sell
-400,000
Closed -$15.1M – 80
2019
Q1 		$15.1M Buy
400,000
+100,000
+33% +$3.36M 0.82% 31
2018
Q4 		$10.3M Buy
+300,000
New +$10.8M 0.78% 30

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Armistice Capital's PTCT Position: Q1 2026 in Review

Armistice Capital reduced its PTC Therapeutics (PTCT) stake by 26% in Q1 2026, selling an estimated $51.5M and leaving 2,074,449 shares worth $141M. The position accounts for 2.51% of the portfolio, ranked #4.

Armistice Capital first reported a position in PTCT in Q4 2018 and has held it in 29 quarters since. The position peaked at $288M in Q4 2024. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Armistice Capital held 2,074,449 shares of PTC Therapeutics worth $141M as of Q1 2026.
  • Armistice Capital sold 727,420 PTC Therapeutics shares in Q1 2026, an estimated $51.5M.
  • PTC Therapeutics made up 2.51% of Armistice Capital's portfolio in Q1 2026, its #4 holding.
  • Armistice Capital first reported a position in PTC Therapeutics in Q4 2018 and has held it in 29 quarters since.
  • Armistice Capital's PTC Therapeutics position peaked at $288M in Q4 2024.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.